The market pattern of contrast agent has basically been formed, how can later the later person intervene?

In recent years, the market size of chinese public hospitals, county-level public hospitals, urban community centers and township hospital terminals has been rising rapidly year by year, with data showing that in 2016-2019, the growth rate was 8.24%, 18.70%, 20.23%, 10.36%, and sales climbed to 15.2 billion yuan in 2019Contrast agent is one of the most commonly used drugs in interventional radiology operations, mainly used in the display of blood vessels and body cavityThere are a variety of contrast agents, and most of the contrast agents currently used in interventional radiology are iodine-containing preparationsAmong them, iodine sea alcohol is a non-ionic contrast agent, is the pharmaceutical factory production of water-soluble, non-ionized X-CT contrast agent raw materialsIodine sea alcohol is also one of the better contrast agents, with high safety, high contrast, low permeability and low human toxicity and many other advantages, so developed countries have completely replaced it with ion-type contrast agent, suitable for spinal cord imaging, cardiovascular, motor veins, lymphatic system, urinary imaging and enhanced CT scanThe market size of iodized sea alcohol preparation is huge, and it is also a large-scale iodine-containing contrast agent in ChinaAccording to statistics, the domestic market size of iodized sea alcohol in 2019 was RMB2,709 million, up 7.54% YoYIn addition, Insight database shows that the current domestic has been approved for listing and the number in the use of iodine sea alcohol injections a total of 57, involving Ningbo Tianheng Pharmaceuticals, General Electric Pharmaceuticals, Hunan Jinjian Pharmaceuticals, Shanghai XudongHai Pu Pharmaceuticals, Huaren Pharmaceuticals, Hunan Hansen Pharmaceuticals, Chenxin Pharmaceuticals, Guizhou Bailing Enterprise Group Pharmaceuticals, Beilu Pharmaceuticals, Yangzijiang Pharmaceuticals, Zhejiang Tianrui Pharmaceutical sAmong them, Yangzijiang, GE and Beilu Pharmaceutical swells the domestic hospital market, the proportion of iodine sea alcohol preparation stake is higherIn addition, only six enterprises have obtained the approval number of API, namely, Zhejiang Shitaili Pharmaceutical, Zhejiang Taizhou Haishen Pharmaceutical (acquired by Shi Taili in 2018), Zhejiang Haichang Pharmaceuticals, Beilu Pharmaceuticals, Zhejiang Anlikang Pharmaceutical Stakes, Guizhou Jingfeng Injection Co., LtdAmong them, The company's production capacity and output ranked in the forefront of the countrySimilar to iodized sea alcohol products also have iodypamol, and iodypamol is currently one of the world's best-selling contrast agentsAccording to Minnet.com, sales of iodized paol in the terminal of public medical institutions in China exceeded 1.1 billion yuan in 2019, with Boleco accounting for 90.26 percent of the market shareIt is understood that iodispart was developed by Bracco (Boleco) in Italy, as a monomer non-ionic contrast agent, the toxicity of blood vessels and nerves are low, local and systemic tolerance is good, penetration is low, injection is also stableThe product was launched in Italy in 1981 and is called IopamiroAt present, the domestic market iodized paol injection manufacturers have Boleco, Beilu Pharmaceuticals, Kangchen Pharmaceuticals, Shi Taili and other 4 enterprisesMrSieli's iodized paol injection was approved for sale on May 12 this year, making it the first domestic reviewNanjing Zhengda Qing's iodine paol injection according to imitation 4 categories of production, if successfully approved will become the second approved enterprise of the varietyAfter nearly a decade of rapid development, the market size of the market has become larger, in 2018 has reached 13.7 billion, 2019 sales climbed to 15.2 billion yuan, is expected to maintain high-speed growth in the next few years, the market pattern has basically formedBut now almost every product market has been firmly controlled by the industry giants, such as Hengrui, Yangzijiang, Boleco, GE, Bayer, Nord-Continental Pharmaceuticals, all of which have been deep-cultivated contrast agents for many yearsTherefore, the industry suggests that for the incoming agent market still need to be cautious, such as the determination and strength of a full-scale entry into the contrast agent market, do not recommend the involvement of non-relevant market resourcesAnd with the contrast agent approval of enterprises, the better choice is undoubtedly with the hospital imaging department resources of the enterprise cooperation sales, such as the recent Division Taili and Hengrui cooperation model is a good example, The Division Taili successfully expand editing upstream business, HengRui further expand edified agent product line, strong joint, jointly deal with policy changes and market competition